Free tool
FAERS Monitor: Bizengri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761352 or its brand name (Bizengri, Zenocutuzumab-Zbco). Reports on generic versions are filed under their own applications.
Reports
10
Serious
4
40% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2
- dysphonia2
- infusion related reaction2
- cardio-respiratory distress1
- diarrhoea1
- disease progression1
- drug intolerance1
- off label use1
- product label confusion1
- product strength confusion1
- product use issue1
- rash maculo-papular1
- sepsis1
- thrombocytopenia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product strength confusion | 1 | 110811.3 | 16359.6 | 26,317 |
| cardio-respiratory distress | 1 | 7387.4 | 1146.5 | 1,839 |
| product label confusion | 1 | 360.9 | 56.2 | 89 |
| rash maculo-papular | 1 | 94.5 | 14.7 | 23 |
| dysphonia | 2 | 71.9 | 20.8 | 78 |
| infusion related reaction | 2 | 63.5 | 18.4 | 69 |
| drug intolerance | 1 | 21.8 | 3.4 | 5 |
| sepsis | 1 | 18.9 | 2.9 | 4 |
| thrombocytopenia | 1 | 18.8 | 2.9 | 4 |
| disease progression | 1 | 17.8 | 2.8 | 4 |
| product use issue | 1 | 11.2 | 1.7 | 2 |
| diarrhoea | 1 | 3.3 | 0.5 | 0 |
| drug ineffective | 2 | 3.2 | 0.9 | 1 |
| off label use | 1 | 2.4 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.